STOCKS TELEGRAPH

Author: ST Staff

  • Liquid Media Group Ltd. (YVR) stock rises during current market trading. Why is it so?

    Liquid Media Group Ltd. (YVR) stock rises during current market trading. Why is it so?

    Liquid Media Group Ltd. (YVR) stock rises by 41.40% in the current market trading session after YVR announced that they are intending to create a multi-token IP platform for which Liquid media has signed a partnership agreement with CurrencyWorks. Liquid Media Group is a business solutions firm that supports independent intellectual property creators.

    What the hype is about?

    Professional video production, packaging, funding, distribution, and monetization would all be possible with YVR’s multi-token platform which will be helping IP creators to take their professional content from conception to monetization. NFTs, utility tokens, and protection tokens will all be part of the multi-token platform’s growth. Depending on regulatory approval, both Liquid Media and CurrencyWorks would keep a limited portfolio of NFTs and Protection Tokens to create a content library, help the artists on their website, and provide future upside for shareholders.

    The CEO of YVR Mr. Ron Thomson said that through this platform engineered by CurrencyWorks, any small or independent content creator’s company can be significantly accelerated and de-risked. Also mentioned that they are excited to assist them with their business solutions, from idea to monetization. YVR would be there from beginning to end.

    Not just that, but also with the help of this platform introduced by YVR professional artists would be able to generate new business opportunities based on digital NFT exclusives and collectibles, increase audience participation, gamify their intellectual property, guarantee recurring licensing fees using smart contracts, provide subscription access through utility tokens, boost project funding through protection tokens, which is huge for the media industry and content creators.

    In short, the Liquid Media Token platform will provide people with

    • Creation
    • Use/Subscription
    • Financing
    • Licensing/Protection.

    Conclusion

    Undoubtedly this new development will sort of revolutionize the media industry. Content creators will be highly benefited through this platform. And following this big enhancement in YVR, its stock price is on the rise because for investors to bet in such a stock is a promising idea.

  • Pyxis Tankers Inc. (PXS) stock Reports Refinancing Of A Previous Loan Facility Securing A Loan Of A Staggering $17M

    Pyxis Tankers Inc. (PXS) stock Reports Refinancing Of A Previous Loan Facility Securing A Loan Of A Staggering $17M

    Pyxis Tankers Inc. (PXS) is a maritime transportation holding tanker company, that has announced that it had officially finished the refinancing of a foregoing loan by obtaining for a financial first position, with a $17 million debt and a traditional interest rate of 3.35% which is to be paid over a 60-month time frame.

    The new load provides the company with several competitive advantages such as a surplus in the balance sheet, and a minimum interest rate and principal payments. The company is stagnant on expanding their mid ranged fleet of product tankers which will provide a surge in operations and earnings. PXS is aiming to diversify its fleet due to restructure cost benefits, establish customer service and a skilful team of managerial staff who are on the same page as the shareholders of the company.

    Pyxis Tankers Inc. (PXS) Announces4th Quarter Result, Reports Loss

    PXS stock stated a quarterly loss of $0.12 per share and announced revenues of approximately $4.5M for the quarter of December, compared to the previous year revenue of $7.26M. PXS Stocks have increased by42.2% since start of this year and has immensely outperformed the S&P gain of 4.1%, which has investors keen on the future of the company.

    PXS had also released 14,285,715 common stocks with each share costing $1.75. The capital gained from the transaction will be used to repay outstanding and acquisition of potential vessels for the company, as well as for corporate purposes

    Conclusion

    PSX is a growth-oriented company which is investing heavily on diversifying its vessels through a loan channel. A substantial increase in the stock price since the start of the year is a positive sign in terms of revenue and has been a healthy indicator for the company’s future valuation.

  • Taoping Inc. (TAOP) stock rises during current market trading. Why is it so?

    Taoping Inc. (TAOP) stock rises during current market trading. Why is it so?

    Taoping Inc. (TAOP) stock rises by 10.35% in the current market trading session after Taoping announced that it has got into a share purchase agreement with Genie Global limited. Taoping is a major manufacturer of smart display terminals and applications for targeted advertisement and online commerce. Customers can distribute and monitor advertisements on cloud-based ad display screens using TAOP’s integrated end-to-end digital advertising solutions.

    Recent Developments.

     

    TAOP joint venture with Genie Global Limited

    Today on March 31, TAOP stock has announced it has got into a share purchase agreement with Genie Global Limited to gain a 51 percent equity interest in Render Lake Tech Ltd that is Genie Global’s wholly owned subsidiary. Render Lake is a cloud technology service provider dedicated to delivering high-performance cloud computing solutions for special effects companies. It was established in 2019 in Ontario, Canada.

    Simultaneously TAOP stock also made an important announcement that they have established NFT Business Division. For this TAOP has appointed Qian Wang as Chief Investment Officer of TAOP, also as the director of NFT Business Division and general manager for Render Lake. Mr. Qian Wang is well known for his expertise in cloud computing services, Blockchain applications and operations, and also for overseas capital market operations.

    TAOP stock closed a strategic cooperation deal

    On March 30, TAOP announced that they have signed a strategic cooperation structure agreement with Shanghai Guanghua Education Investment Management and Wuhu Sasan Education Management that is a majority-owned subsidiary of Shanghai Guanghua Education for the time span for next three years. Shanghai Guanghua Education, founded in 1999, is a provider of educational technology services, including educational technology system creation, educational course content development, educational business investment, advisory and management, and technical equipment and stationery sales.

    TAOP and Wuhu Sasan plan to form a joint venture company in Wuhu, China, as part of the deal. Also TAOP stock and Wuhu Sasan will each own 51 percent and 49 percent of the joint venture’s equity, respectively.  The joint venture company’s operations are expected to fall under TAOP’s newly formed Digital Culture Business Division.

    Conclusion

    Following the two major developments in Taoping, the rise in its stock price is fairly justified. If the two agreements turn out to be successful in the near time, it will be highly beneficial for TAOP but right now investors seem to be interested in making long-term bets, hence the TAOP stock price is on the rise.

  • Why Delcath Systems, Inc. (DCTH) stock is falling today?

    Why Delcath Systems, Inc. (DCTH) stock is falling today?

    Delcath Systems, Inc. (DCTH) announced its fourth-quarter 2020 results after which the DCTH stock price happened to be down by 24.54% to drop at $12.28 a share as of this writing. At the previous trading session, DCTH stock was performing well and gained 1.37% at closing. Let’s understand more about the current scenarios.

    Fourth Quarter 2020 Results:

    • DCTH stock product revenue reduced to $379 thousand in the fourth quarter of 2020 as compared to $398 thousand in the same quarter of the previous year.
    • Selling, general and administrative expenses increased by $2.4 million to reach $4.5 million in the last three months of 2020 as compared to $2.1 in the same period of 2019.R&D expenses showed no change and were totaled $2.7 million.
    • Operating expenses surged to $7.3 million while these were $4.8 million in the same period of 2019.
    • DCTH suffered a net loss of $7.0 million in the fourth quarter of 2020 while it recorded a net income of $12.5 million in the same period of 2019.
    • DCTH stock had cash, cash equivalents, and restricted cash of $28.8 million as of 31 December 2020 and it used  $4.6 million cash in its operating activities during the last three months of 2020 while this cash was recorded as $5.4 million for operational activities of 2019.

    Business Highlights in last three months:

    • Delcath Systems was performing phase three FOCUS Clinical Trial of HEPZATO in patients suffering from Metastatic Ocular The results were positive and above expectations. This preliminary analysis includes 87% of patients and final results are expected to come soon in the future.
    • DCTH started consulting engagement for the selection of a portfolio of follow-on-indications in order to increase HEPZATO Kit and CHEMOSAT platform value.
    • DCTH stock completed a public offering of shares of its common stock which resulted in gross proceeds of $22.2 million.
    • Gerard Michel was appointed as the Chief Executive officer by the Delcath stock while Kevin Muir was assigned the role of Vice President for commercial

    Conclusion

    Things are going against the DCTH stock after the earnings release by Delcath Systems. Product revenue was reduced in 2020 while expenses were increased over the year. It would be interesting to see how new management would drive Delcath in the future.

  • NovaBay Pharmaceuticals (NBY) stock soared in the recent trading session: here’s why

    NovaBay Pharmaceuticals (NBY) stock soared in the recent trading session: here’s why

    NovaBay Pharmaceuticals (NBY) stock recently traded at $0.92 which is a 4.20% upward movement. The NBY stock previously closed at $0.87.

    The pattern of positive movement in recent trading session comes along with the announcement made by NovaBay Pharmaceuticals (NBY) about its Avenova being available now on Amazon.com and Avenova.com.

    Glimpse into the workings of the biopharmaceutical company

    NovaBay Pharmaceuticals, Inc. (NBY) is a biopharmaceutical company that is focused on creating anti-infective consumer products which are of high-end and unmatched efficacy in the market. Specifically for the development of high-end anti-infective consumer product, NovaBay Pharmaceuticals (NBY) use hypochlorous acid as the main formula ingredient. This hypochlorous acid is patented and is stable pharmaceutical grade quality. This acid is effective in creating the same efficacy as antimicrobial chemicals used by white-blood cells to fight infection.

    What are the main products of NovaBay (NBY)

    NBY stock has many consumer health products. Most popular of its consumer products consist of Avenovawhich is a proprietary antimicrobial lid and lash spray. The second is CelleRx Clinical Reset which is a more beauty oriented cosmetic product. The third is NeutroPhase which is a disinfectant that cleans and repairs skin wounds.

    NovaBay has started commercialization of Avenova. NBY stock has specifically released Warm Eye Compress which is going to be available on the online platforms. Avenova Warm Eye Compress can be used together with Avenova anti-microbial spray.

    What makes Avenova anti-microbial spray and Warm Eye Compress a good combo?

    What is unique about Avenovaanti-microbial is that it is the only commercially available Hypochlorous acid which has a bonus feature of being clinically proved to reduce bacteria on ocular skin surface. It is used to mostly get rid of bacterial dry eye.

    Warm Eye Compress helps get rid of the dryness in the eye which causes inadequate lubrication and can cause tear production to become poor quality. Why this happens, is mainly a symptom of bacterial dry eye.

    Warm Eye Compress when used with a combination of Avenova anti-microbial spray allows eyes to restore their own natural defense ocular dryness and improve tear production quality. Avenova’s Warm Eye Compress does this by stimulating meibomian glands that are in the tear-ducts. The glands then produce tears which clean it up and retain the natural oils in the eye. These natural oils then prevent the evaporation of the tear while the Compress overall improves the blood circulation of the eyes.

    Full year financial report and overlook of the NBY stock

    Previously on 25th March, The NBY stock released the quarterly and full-year 2020 report of its financial results. The Fourth Quarter sales had reached a new record which was driven primarily by online sales, as is the setting trend of the year 2020 due to the pandemic.

    NovaBay has overall performed impressively in the year 2020 in which its net product revenue was $9.9 million; a 51% increase from 2019’s net product revenue. NBY stock also exited 2020 with 12$ million cash and cash equivalents. The solid fundamentals have allowed NBY stock to expand its market reach to CVS stores and CVS online. Solid fundamentals and a plan of effective operation expansion is what attracts investors for the long term.

  • Athersys, Inc. (ATHX) stock Rises in Pre-Market: Let’s find out why.

    Athersys, Inc. (ATHX) stock saw a more push in today’s pre-market trading session after the spread of the news that Athersys partner HEALIOS K.Khas completed the enrollment in the ONE-BRIDGE study in Japan. ATHX stock price saw an uptrend of  3.66% to reach $1.70 a share at the time of this writing. ATHX stock seemed green at the previous trading session and closed with a 1.86% gain. Let’s understand the current happenings.

    The ONE-BRIDGE study:

    One Bridge Study suggests the evaluation of the MultiStem® (invimestrocel) in patients who are suffering from acute respiratory distress syndrome (ARDS) which is mainly caused by pneumonia. One Bridge study comprises two patient groups. One group includes 30 patients who are suffering ARDS due to pneumonia. The second group consists of 5 patients suffering from ARDS due to COVID-19. The main objective is to compare the results of the safety and efficacy of Multistem treatment in both groups.HEALIOS will analyze this data after the follow-up period and then further announce the results.

    Athersys is conducting its study named MACOVIA in the united states in order to analyze the results of Multstem against the treatment of COVID-19 induced ARDS patients. One thing is to remember that FDA had given both Fast Track and Regenerative Medicine Advanced Therapy approval to the ARDS program.

    Financial View of ATHX stock

    ATHX announced its fourth quarter and fiscal year 2020 results in which ATHX stock generated $1.3 million in the last three months of 2020 as compared to the same period in 2019 while full-year revenue decreased to $1.4 million as compared to $5.6 million revenue in 2019.R&D expenses increased significantly to $18.7 million in the fourth quarter of 2020 as compared to $7.6 million in the prior year while overall R&D expenses for the full year 2020 reached $63 million as compared to $39 million in 2019. General and administrative expenses of ATHX stock were $4.3 million in the last three months while these were $15.9 for the full year of 2020.

    As of December 31, 2020, Athersys stock had 51.5 million in cash and cash equivalents while these were $35.0 million on December 31, 2019.

    Conclusion:

    It seems that momentum was already built for ATHX stock in the previous trading session and recent news of ATHX stock has added more hype to it. The earnings report suggests that Athersys contract revenue from its collaboration with Healios has decreased over the year, but operational expenses show that ATHX stock has progressed over the year. In a nutshell, investors should analyze ATHX stock both fundamentally and technically.

  • Savara Inc. (SVRA) stock gains in Pre-Market: Things you need to know

    Savara Inc. (SVRA) stock gains in Pre-Market: Things you need to know

    Shares of Savara Inc. (SVRA) continued to gain in Wednesday’s pre-market trading session. SVRA stock price saw an uptrend of 7.46% to reach $2.09 a share as of this writing. Savara stock was up by 21.56% at the previous closing. It seems that analyst rating is driving the SVRA stock price to high. Let’s understand the bullish sentiment in depth.

    Analyst Review on SVRA stock.

    Savara Inc. (SVRA) is working as an orphan disease lung company mainly focused on autoimmune pulmonary alveolar proteinosis (aPAP), a disease in which excessive protein in the lungs causes difficulty in breathing.

    Savara was performing well in the previous trading session and continuing the trend so far. Some of the street members believe that the current share price of SVRA stock points to the effective entry point. A famous piper sandler analyst Yasmeen Rahimi has given the buy rating to SVRA stock and set a $7 target price which suggests that SVRA stock has the potential to soar over 309% in the coming year.

    Rahimi thinks that Molgradexhas the great potential to treat autoimmune pulmonary alveolar proteinosis (PAP) and would be proved to be game-changer therapeutic in the future. Hence there is a strong possibility that SVRA stock would outperform in the future. The analyst further depicted the validation of Molgradex by saying that it has already received the Orphan Drug Designation in the U.S for seven years and EU for ten years in addition to Fast Track Designation and Breakthrough Therapy Designation by FDA.

    Previous Event

    Savara stock announced the public offering of shares of its common stock on March 10, 2021, which SVRA closed on March 15, 2021. A total of  57,479,978 shares were included in that offering at $1.45 per share. The net proceeds resulted from this offering were intended to support the working capital of Savara’s operations in different sectors.

    Conclusion:

    Savara stock is rising as investors are responding in response to the analyst rating. The three recent reviews of Buy with an average target price of $4.67 point to the 173% growth for this penny stock in the next year. Hence SVRA stock can be a good bet in long run.

  • FrieghtCar America Inc. (RAIL) stock soared in the pre-market trading session: here’s why

    FreightCar America Inc. (RAIL) stock recently traded at $4.86 which is a 0.21% upward movement. The stock previously closed at $4.85. However, in the pre-market trading session, RAIL stock soared by 8.44% at the time of writing.

    The pattern of positive movement of RAIL stock in the recent pre-market trading session comes with no sort of recent news or Company press release. However, FrieghtCar (RAIL) did release its Q4 and FY 2020 report on 24th March 2021 which had overall positive fundamentals for the company in 2020.

    How does FreightCar America (RAIL) operate its business?

    FreightCar America Inc. is a railroads company specifically focused on manufacturing railroad freight cars. FrieghtCar has diversified its portfolio in the rail-industry market by also producing and supplying railcar parts which also includes specialization in the conversion of old railcars for repurposed uses.FreightCar (RAIL) manufactures topline railcars that include a series of hopper cars and build intermodal and non-intermodal cars. Coal cars, box cars, and mil gondola cars are also part of its multiple asset portfolios. RAIL stock has a subsidiary by the name of FrieghtCar American Leasing Company which provides leases for freight cars.

    How RAIL stock uplifted itself during the Pandemic?

    The investors gained confidence in the RAIL stock on 24th March 2021, when FreightCar released its financial report on fourth quarter and full year report 2020. Despite the pandemic forcing businesses to go through their potentially toughest financial year in 2020, FreightCar’s2021 guidance looks positive even though it took some losses. The rail company went through a restructuring-stage and is now finally in growth stage. FreightCar moved their manufacturing operations from Alabama to Castanos and in North America, where it has the newest purpose-built railcare manufacturing facility. This facility became operational in the fourth quarter of 2020.

    FreightCar America Inc.’s (RAIL) Q4 and Full Year Report

     

    Here are the Fourth Quarter and Full Year Highlights

    • The consolidated revenues forQ4 2020 were $60.6 million compared to $44.9 million in Q4 2019
    • The consolidated loss for Q4 2020 was $9.2 million compared to $9.0 million in Q4 2019
    • Net loss for the RAIL stock attributed to $14.4 million or $0.87 per share in Q4 2020. In Q4 2019 it was $9.5 million or $.75 per share.
    • The consolidated revenues for 2020 FY were $108.4 million while it was $230 million for 2019 FY.
    • 751 Railcars were delivered in 2020 while 2,276 railcars were delivered in 2019.
    • The consolidated operating loss for 2020 was $80.6 million while for 2019 it was $75.6 million.
    • Inventories in 2020 were totaled at $38.8 million compared to $25.1 million in 2019
    • Cash equivalents, restricted cash equivalents and marketable securities equals to $54.2 million at the year ending 2020, while $70 million at the year ending 2019.

     

    Outlook projection for FreightCar America Inc (RAIL)

    The expansion into Mexico is positive news for the RAIL stock. The facility has the capacity to produce 2,000 railcars per year. Castanos facility also has gotten approval for the inclusion of large fabrication shop along with additional wheel and axle capacity.

    The most significant aspect of the financial report in terms of future outlook is the provision of delivery guidance for 2021 by FreightCar. RAIL stock estimates that it will have 1400 to 1600 railcars in 2021. The CEO of FreightCar America Inc. Jim Meyer projects that their total deliveries will be a double in 2021.

  • Hywin Holding Ltd. (HYW) stock rises during the pre-market trading. Let’s find out why?

    Hywin Holding Ltd. (HYW) stock rises during the pre-market trading. Let’s find out why?

    Hywin Holding Ltd. (HYW) stock surged by 2.5% in the last trading close whereas the HYW stock continued to rise by 2.35% in the pre-market trading session. According to CIC, Hywin is China’s 3rd biggest third-party wealth management service provider, with a 7.5 percent share of the market of 2019 transaction volume. Wealth management, insurance brokerage, and asset management are our key offerings. The upstream and downstream solution platform of Hywin Holding supports clients through generations of wealth management, which is currently their largest market segment. This division promotes and distributes investment goods and funds that collect money privately and publicly.

    What is happening?

    On March 30, 2021, Deutsche Bank announced that they have been designated as depositary bank for Hywin Holdings NASDAQ-listed American Depositary Receipt scheme. The Bank with its wide range of customized services is expected to provide efficient services in assisting HYW for its ADR program. This recent initiative of HYW could be the reason behind the rise in HYW stock.

    Past Development:

    Public Offering

    On March 26, 2021, HYW revealed the pricing of its 3,000,000 American Depositary Shares (ADS) initial offering, which was priced at US$10.00 per ADS. Each ADS was representing two of HYW’s ordinary Class A shares. On the same day, the ADSs started with trading on the NASDAQ Global Market under the ticker symbol “HYW.” Depending on the customary closing conditions, the offering was scheduled to close on March 30, 2021.

    The Company has given the underwriters an option to buy up to 450,000 additional ADSs, exercisable within 45 days of the date of the final prospectus. Before deducting underwriting discounts and commissions and other offering expenses incurred by HYW, the gross proceeds from the offering to HYW are estimated to be about $30 million, exclusive of use of the underwriters’ option to buy additional stock. And the book runners for the offering are Network 1 Financial Securities, Alexander Capital and Valuable Capital Limited.

  • ReneSola (SOL) stock soared in the recent trading session: here’s why

    ReneSola (SOL) stock soared in the recent trading session: here’s why

    ReneSola (SOL) stock recently traded at $11.84 which is a 20.82% upward movement. The ReneSola stock previously closed at $9.80.

    The recent positive movement in the stock was adjacent to the release of the financial result of the fourth quarter of 2020.

    Glimpse into the leading Global Solar Power Company

    ReneSola (NYSE: SOL) is a Solar based company specifically a developer and operator of solar projects. The company’s portfolio consists of the development of solar power projects, construction management, and project financing services. ReneSola is a global company and has deployed professional teams across 10 countries.

    With solar power projects growing around the world, ReneSola (SOL) has effectively strategized the expansion of its operations in regions where this phenomenon is on the rise. The regions specifically consist of US and European markets; New York, Minnesota, Poland and Hungary.

    ReneSola (SOL) misses revenue target and loses investor confidence

    Even with the market-leading positions in several geographies, SOL stock does not show the effectiveness of these positions on its balance sheet. ReneSola(SOL) missed on its revenue target in the Q4 2020. The earnings however were breakeven for the American Depositary Share.

    Zacks Consensus Estimate of revenue earning for Q4 2020 was $25 million while SOL stock was able to generate $16.8 million and missed the estimate by 31.8%. Furthermore, ReneSola’s own projection for the quarter was around $23-$25 million.

    As for the Full-Year report, the revenues were reported at $73.9 million while the SOL’s guidance had an expectation of $80-$100 million. This FY 2020 revenue is weaker in comparison to FY 2019’s $119.1 million.

    Cash Equivalent Finances

    As of the end of the year 2020, ReneSola (SOL) had cash and cash equivalent of $40.6 million. This is a 59% increase than that of $24.3 million on 31st Dec, 2019. Let’s look at the operational activities of the SOL stock.

    Operational activities of ReneSola (SOL)

    Operating expenses were drastically down to $1.5 million – a 92.6% down from the $20.4 million witnessed on the Q4 on 2019. ReneSola generated a gross margin of 14.7% in the fourth quarter of 2020 as compared to 26.9% of the year-ago quarter.

    Income generated through operational activities in the fourth quarter totaled at $0.96 million. However, in the last year in the same quarter in operated at a loss of $13.3 million.

    Recent Solar Projects completed

    The SOL stock has 828 MW of projects completed in the year 2020. While the number of late-stage projects totaled at 1 GW. The rooftop projects operation in the year 2020 comprised of 173 MW out of which 149.2 are present in China and 24.1 are in the United States.

    SOL stock’s estimate and guidance for the year 2021

    The SOL stock has also given quarterly and full-year guidance for the year 2021. For the first quarter, ReneSola (SOL) expects revenue of $18-$20 million while the ZCE is projected at $24.6 million. Similarly, for the Full Year 2021, the company-projection is in the range of $90-$100 million while the ZCE has pegged the revenues at $161.4 million which is again much higher than the SOL stock projection.